Raymond1109 personal page - To The Moon

Raymond1109

Raymond1109

No personal profile

16Follow

7Followers

0Topic

0Badge

2021-04-29

$Histogenics(OCGN)$FDA kindly approve histo for emergency use ?????

2021-05-04

$Histogenics(OCGN)$FDA & EUA soon ???????

2021-05-04

$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Phase 3 trail gotta succeed soon! Comeon! ???????

2021-05-04

$Microvision(MVIS)$Where’s the Reddit push to $100? Hahahah

2021-05-04

$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Silent for way too long~ something should be cooking soon!!

2021-06-21

Note to self~

Sorry, the original content has been removed

2021-06-14

Naked gogogo

Sorry, the original content has been removed

2021-04-30

$Histogenics(OCGN)$Time to fly high, soar away!! ??

2021-04-27

$Histogenics(OCGN)$Awaiting the FDA approval~

2021-05-13

$iPower Inc.(IPW)$??????

2021-05-08

$Microvision(MVIS)$Hodl only, only next week can see abit more of greens~

2021-07-05

Time to soar!

Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19

2021-05-27

May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite

BRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin

2021-05-14

$Naked Brand(NAKD)$18-20% surge can’t be all we got right…. ☝?☝?

2021-05-14

$Naked Brand(NAKD)$+8% to +10% now, what are the chances post market +50%? Hmm ?

2021-05-10

$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Today financial report, hope all is good ?? it has been WAYYYYY too long since there is any much movement from this!

2021-04-29

$Histogenics(OCGN)$It’s about time right?

2021-04-29

$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Really need to hold till clinical trial phase 3 to see it ? again

2021-04-27

$Histogenics(OCGN)$Time to soar ?? 14-15 tomorrow will be good ????

2021-07-05

Great ariticle, would you like to share it?

@koonkoon:$Histogenics(OCGn)good news

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582000739695630","uuid":"3582000739695630","gmtCreate":1618938827256,"gmtModify":1618972651960,"name":"Raymond1109","pinyin":"raymond1109","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":16,"tweetSize":48,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.31","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.04%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"60.74%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":154946922,"gmtCreate":1625473168066,"gmtModify":1703742360407,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Time to soar!","listText":"Time to soar!","text":"Time to soar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154946922","repostId":"2148801599","repostType":2,"repost":{"id":"2148801599","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625576711,"share":"https://ttm.financial/m/news/2148801599?lang=en_US&edition=fundamental","pubTime":"2021-07-06 21:05","market":"us","language":"en","title":"Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2148801599","media":"Reuters","summary":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, ha","content":"<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen says Indian partner's vaccine 93.4% effective against severe COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-06 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148801599","content_text":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154941707,"gmtCreate":1625473069409,"gmtModify":1703742357615,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154941707","repostId":"155231719","repostType":1,"repost":{"id":155231719,"gmtCreate":1625438214331,"gmtModify":1703741555205,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564546889826365","idStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCG</a>n)good news","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCG</a>n)good news","text":"$Histogenics(OCGn)good news","images":[{"img":"https://static.tigerbbs.com/289870db1bfd26ce1e7e3a3fe788f25c","width":"1080","height":"975"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/155231719","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152237822,"gmtCreate":1625295203366,"gmtModify":1703740160147,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Yeah boiii~","listText":"Yeah boiii~","text":"Yeah boiii~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152237822","repostId":"2148801599","repostType":2,"repost":{"id":"2148801599","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625576711,"share":"https://ttm.financial/m/news/2148801599?lang=en_US&edition=fundamental","pubTime":"2021-07-06 21:05","market":"us","language":"en","title":"Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2148801599","media":"Reuters","summary":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, ha","content":"<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen says Indian partner's vaccine 93.4% effective against severe COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-06 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148801599","content_text":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126884085,"gmtCreate":1624551241047,"gmtModify":1703840261038,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Gogogo ~","listText":"Gogogo ~","text":"Gogogo ~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126884085","repostId":"126046481","repostType":1,"repost":{"id":126046481,"gmtCreate":1624539809643,"gmtModify":1703839745435,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"themes":[],"htmlText":"Check this You Tube from this Investors --&nbsp;interesting read. Average Shorties 16%-20%, average Long is 80%-84%. It’s quite stable. Strongly recommended to hold till $10. Cheers!&nbsp;https://youtu.be/6ZLYVb8HmlA","listText":"Check this You Tube from this Investors --&nbsp;interesting read. Average Shorties 16%-20%, average Long is 80%-84%. It’s quite stable. Strongly recommended to hold till $10. Cheers!&nbsp;https://youtu.be/6ZLYVb8HmlA","text":"Check this You Tube from this Investors -- interesting read. Average Shorties 16%-20%, average Long is 80%-84%. It’s quite stable. Strongly recommended to hold till $10. Cheers! https://youtu.be/6ZLYVb8HmlA","images":[{"img":"https://static.tigerbbs.com/a882c72deb9cc00e00761e8aec2b7832","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/126046481","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2386,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128289730,"gmtCreate":1624518478120,"gmtModify":1703839113417,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Sounds like OCGN linked ? hahaha","listText":"Sounds like OCGN linked ? hahaha","text":"Sounds like OCGN linked ? hahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128289730","repostId":"2145198180","repostType":2,"isVote":1,"tweetType":1,"viewCount":2049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129222000,"gmtCreate":1624374578800,"gmtModify":1703834908053,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Interesting~","listText":"Interesting~","text":"Interesting~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129222000","repostId":"129132467","repostType":1,"repost":{"id":129132467,"gmtCreate":1624364306159,"gmtModify":1703834423584,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Check this out guys!&nbsp;","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Check this out guys!&nbsp;","text":"$Histogenics(OCGN)$Check this out guys!","images":[{"img":"https://static.tigerbbs.com/cccdea4ad529ce5300dc28629a8de1d1","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129132467","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2248,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129221773,"gmtCreate":1624374502792,"gmtModify":1703834905106,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Come on come on!","listText":"Come on come on!","text":"Come on come on!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129221773","repostId":"129962987","repostType":1,"repost":{"id":129962987,"gmtCreate":1624352277249,"gmtModify":1703834178471,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Check&nbsp;this out. Covaxin Phase 3 Trial Data Shared With Expert Panel Which Meets Today:&nbsp;https://www.ndtv.com/india-news/covaxin-phase-3-trial-data-bharat-biotech-submits-phase-3-trial-data-expert-committee-to-meet-today-2469383","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Check&nbsp;this out. Covaxin Phase 3 Trial Data Shared With Expert Panel Which Meets Today:&nbsp;https://www.ndtv.com/india-news/covaxin-phase-3-trial-data-bharat-biotech-submits-phase-3-trial-data-expert-committee-to-meet-today-2469383","text":"$Histogenics(OCGN)$Check this out. Covaxin Phase 3 Trial Data Shared With Expert Panel Which Meets Today: https://www.ndtv.com/india-news/covaxin-phase-3-trial-data-bharat-biotech-submits-phase-3-trial-data-expert-committee-to-meet-today-2469383","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129962987","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120366509,"gmtCreate":1624301200701,"gmtModify":1703832917219,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"????????","listText":"????????","text":"????????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/120366509","repostId":"167542426","repostType":1,"repost":{"id":167542426,"gmtCreate":1624279535665,"gmtModify":1703832258199,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Phase 3 Clinically trials results submitted over the weekend. Cheers Everyone!&nbsp;","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Phase 3 Clinically trials results submitted over the weekend. Cheers Everyone!&nbsp;","text":"$Histogenics(OCGN)$Phase 3 Clinically trials results submitted over the weekend. Cheers Everyone!","images":[{"img":"https://static.tigerbbs.com/2f9c323292adba33d21f8925c3d4b921","width":"1242","height":"2688"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/167542426","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2701,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164587366,"gmtCreate":1624230013555,"gmtModify":1703830813306,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Note to self~","listText":"Note to self~","text":"Note to self~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164587366","repostId":"1126454279","repostType":2,"isVote":1,"tweetType":1,"viewCount":1919,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187176592,"gmtCreate":1623748052316,"gmtModify":1704210300731,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"IPO are always like a gamble HAHAHA&nbsp;","listText":"IPO are always like a gamble HAHAHA&nbsp;","text":"IPO are always like a gamble HAHAHA","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187176592","repostId":"1175897310","repostType":4,"repost":{"id":"1175897310","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1623725513,"share":"https://ttm.financial/m/news/1175897310?lang=en_US&edition=fundamental","pubTime":"2021-06-15 10:51","market":"us","language":"en","title":"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=1175897310","media":"Benzinga","summary":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is ","content":"<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-06-15 10:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.</p>\n<p><b>AMTD Digital:</b>Asian digital solutions platform&nbsp;<b>AMTD Digital</b>(NYSE:HKD)&nbsp;offers&nbsp;risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.</p>\n<p><b>Molecular Partners:</b>Clinical stage biotechnology company&nbsp;<b>Molecular Partners</b>(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with&nbsp;<b>Novartis</b>(NYSE:NVS) in 2020,<b>Amgen Inc</b>(NASDAQ:AMGN) in 2018 and&nbsp;<b>AbbVie Inc</b>(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.</p>\n<p><b>WalkMe:</b>With a mission to change the way humans interact with technology,<b>WalkMe</b>(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.</p>\n<p>WalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.</p>\n<p><b>Convey Holding:</b>Health care company&nbsp;<b>Convey Holding</b>(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.</p>\n<p><b>Angel Oak Mortgage:</b>Real estate finance company&nbsp;<b>Angel Oak Mortgage</b>(NYSE: AOMR)&nbsp;acquiresand invests in first&nbsp;lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.</p>\n<p><b>Lyell Immunopharma:</b>Seeking to disrupt the T-cell reprogramming market,<b>Lyell ImmunoPharma</b>(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered with<b>GlaxoSmithKline</b>(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.</p>\n<p>GlaxoSmithKline owns 14% of Lyell and&nbsp;<b>Bristol-MyersSquibb</b>(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.</p>\n<p><b>Verve Therapeutics:</b>Genetic medicine company<b>Verve Therapeutics</b>(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.</p>\n<p><b>Atai Life Sciences:</b>Backedby&nbsp;<b>Palantir Technologies</b>(NYSE:PLTR) and&nbsp;<b>Paypal Holdings</b>(NASDAQ:PYPL) founder Peter Thiel,<b>Atai Life Sciences</b>(NASDAQ:ATAI) could be one of the high profile IPOs of the week.</p>\n<p>The company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.</p>\n<p><b>AiHui Shou International:</b>Pre-owned consumer electronics reseller&nbsp;<b>AiHuiShou International</b>(NYSE: RERE)seeksto give a second life to all idle goods.</p>\n<p>The company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.<b>JD.com</b>(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LYEL":"Lyell Immunopharma, Inc.","NVS":"诺华","ATAI":"Atai Beckley Inc","HKD":"尚乘数科","RERE":"爱回收","AOMR":"ANGEL OAK MORTGAGE REIT INC","MOLN":"Molecular Partners AG","WKME":"WalkMe Ltd."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1175897310","content_text":"This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.\nAMTD Digital:Asian digital solutions platform AMTD Digital(NYSE:HKD) offers risk solutions and digital insurance technology for partners. The company had revenue of $21.6 million in fiscal 2020 and $18.8 million through the first nine months of the current fiscal year. The company plans to sell 16 million ADSs at a price point of $6.80 to $8.20.\nMolecular Partners:Clinical stage biotechnology company Molecular Partners(NASDAQ:MOLN) isfocusedon using its pioneering DARPin product in categories including infectious diseases, oncology and ophthalmology. The company partnered with Novartis(NYSE:NVS) in 2020,Amgen Inc(NASDAQ:AMGN) in 2018 and AbbVie Inc(NYSE:ABBV) in 2011. Novartis owns 6% of the company. Molecular Partners plans to sell 3 million ADS.\nWalkMe:With a mission to change the way humans interact with technology,WalkMe(NASDAQ:WKME)offerssolutions for organizations. The company has many well-known companies as customers including Nestle and Veolia, two large European companies listed as case studies in the filing.\nWalkMe had revenue of $148 million in 2020 and revenue of $42.7 million in the first quarter of 2021. The company’s revenue was up 34% year-over-year in the last twelve months. The company has 368 customers that represent $100,000 or more in annual revenue and 22 customers that represent $1 million or more in annual revenue. WalkMe plans on selling 9.25 million shares at a price point of $29 to $32.\nConvey Holding:Health care company Convey Holding(NYSE:CNVY)partnerswith eight of the 10 largest Medicare Advantage companies in the U.S. The company had 2.5 million Medicare Advantage and 1.6 million Prescription Drug Plan members in 2020. Revenue in 2020 for the company was $282.9 million. First-quarter 2021 revenue was $82.6 million for the company. Convey Holding plans to sell 13.3 million shares at a price point of $14 to $16.\nAngel Oak Mortgage:Real estate finance company Angel Oak Mortgage(NYSE: AOMR) acquiresand invests in first lien non-QM Loans and other mortgage assets in the U.S. The company had assets of $534.9 million at the end of the first quarter of 2021. The company has elected to be taxed as a REIT. Angel Oak Mortgage is seeking to sell 8.1 million shares at a price point of $20 to $21.\nLyell Immunopharma:Seeking to disrupt the T-cell reprogramming market,Lyell ImmunoPharma(NASDAQ:LYEL)intendsto have four INDs submitted by the end of 2022. The company partnered withGlaxoSmithKline(NYSE:GSK) in 2019 in a deal good for up to $400 million in additional milestones after a $45-million upfront payment.\nGlaxoSmithKline owns 14% of Lyell and Bristol-MyersSquibb(NYSE:BMY) owned Celgene owns 5% of the company. Lyell is planning to sell 25 million shares at a price point of $16 to $18.\nVerve Therapeutics:Genetic medicine companyVerve Therapeutics(NASDAQ: VERV) isfocusedon cardiovascular disease. The company plans to sell 11.8 million shares at a price point of $16 to $18.\nAtai Life Sciences:Backedby Palantir Technologies(NYSE:PLTR) and Paypal Holdings(NASDAQ:PYPL) founder Peter Thiel,Atai Life Sciences(NASDAQ:ATAI) could be one of the high profile IPOs of the week.\nThe company isdevelopingtreatment options for mental health disorders. The company has 10 programs in its pipeline and six enabling technologies. The company is planning on selling 14.3 million shares at a price point of $13 to $15.\nAiHui Shou International:Pre-owned consumer electronics reseller AiHuiShou International(NYSE: RERE)seeksto give a second life to all idle goods.\nThe company’s three business lines — AHS Recycle, PJUT Marketplace and PaiPai Marketplace — help the company as the market leader in China with a market share of 6.6%. The company had revenue of $741.5 million in 2020 and $231.1 million in the first quarter of 2021, up 119% year-over-year.JD.com(NASDAQ:JD) will own 32.3% of the company after the IPO. The company plans on selling 16.2 million ADSs at a price point of $13 to $15.","news_type":1,"symbols_score_info":{"MOLN":0.9,"HKD":0.9,"ATAI":0.9,"AOMR":0.9,"NVS":0.9,"CNVY":0.9,"LYEL":0.9,"WKME":0.9,"RERE":0.9}},"isVote":1,"tweetType":1,"viewCount":1970,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187171945,"gmtCreate":1623748001487,"gmtModify":1704210297151,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Damnnnn","listText":"Damnnnn","text":"Damnnnn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187171945","repostId":"2143178756","repostType":4,"isVote":1,"tweetType":1,"viewCount":795,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185502638,"gmtCreate":1623658135724,"gmtModify":1704207966754,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Naked gogogo","listText":"Naked gogogo","text":"Naked gogogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/185502638","repostId":"1149061517","repostType":2,"isVote":1,"tweetType":1,"viewCount":773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185273826,"gmtCreate":1623657289865,"gmtModify":1704207946475,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/185273826","repostId":"1105297799","repostType":4,"isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188112615,"gmtCreate":1623423988837,"gmtModify":1704203415153,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Woah naise!","listText":"Woah naise!","text":"Woah naise!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188112615","repostId":"1158585683","repostType":4,"repost":{"id":"1158585683","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623418302,"share":"https://ttm.financial/m/news/1158585683?lang=en_US&edition=fundamental","pubTime":"2021-06-11 21:31","market":"us","language":"en","title":"Dow rises 80 points, S&P 500 adds to a record as tech shares gain","url":"https://stock-news.laohu8.com/highlight/detail?id=1158585683","media":"Tiger Newspress","summary":"(June 11) U.S. stocks rose on Friday with the S&P 500 adding to its new record, as Wall Street aims ","content":"<p>(June 11)&nbsp;U.S. stocks rose on Friday with the S&amp;P 500 adding to its new record, as Wall Street aims to wrap up the week on a high note.</p>\n<p>The Dow Jones Industrial Average gained 100 points while S&amp;P 500 added 0.2% after closing at a record in the previous session. Nasdaq-100 futures gained 0.1%. Apple, Amazon, Netflix, Microsoft and Alphabet all traded in the green.</p>\n<p>There were not many big movers in premarket trading. Some of the meme stocks were rebounding after a rough day on Thursday. AMC shares were up 3% and GameStop was up 7% in the premarket. Those twosuffered double digit percent losseson Thursday as momentum in the Reddit favorites faded.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow rises 80 points, S&P 500 adds to a record as tech shares gain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow rises 80 points, S&P 500 adds to a record as tech shares gain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-11 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 11)&nbsp;U.S. stocks rose on Friday with the S&amp;P 500 adding to its new record, as Wall Street aims to wrap up the week on a high note.</p>\n<p>The Dow Jones Industrial Average gained 100 points while S&amp;P 500 added 0.2% after closing at a record in the previous session. Nasdaq-100 futures gained 0.1%. Apple, Amazon, Netflix, Microsoft and Alphabet all traded in the green.</p>\n<p>There were not many big movers in premarket trading. Some of the meme stocks were rebounding after a rough day on Thursday. AMC shares were up 3% and GameStop was up 7% in the premarket. Those twosuffered double digit percent losseson Thursday as momentum in the Reddit favorites faded.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158585683","content_text":"(June 11) U.S. stocks rose on Friday with the S&P 500 adding to its new record, as Wall Street aims to wrap up the week on a high note.\nThe Dow Jones Industrial Average gained 100 points while S&P 500 added 0.2% after closing at a record in the previous session. Nasdaq-100 futures gained 0.1%. Apple, Amazon, Netflix, Microsoft and Alphabet all traded in the green.\nThere were not many big movers in premarket trading. Some of the meme stocks were rebounding after a rough day on Thursday. AMC shares were up 3% and GameStop was up 7% in the premarket. Those twosuffered double digit percent losseson Thursday as momentum in the Reddit favorites faded.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":537,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181428755,"gmtCreate":1623408131377,"gmtModify":1704202775635,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Can consider ?&nbsp;","listText":"Can consider ?&nbsp;","text":"Can consider ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181428755","repostId":"2142268662","repostType":4,"isVote":1,"tweetType":1,"viewCount":801,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181429550,"gmtCreate":1623408011070,"gmtModify":1704202772873,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Let’s go!!","listText":"Let’s go!!","text":"Let’s go!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181429550","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1704195267674,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/44a4f89726b3f6319d06a0075bf9ff76","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【老虎7週年】集卡瓜分百萬獎金","htmlText":"老虎7週年給大家發福利了，集齊TIGER五個字母即有機會瓜分百萬獎金，你準備好了嗎？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可參與活動</a> &#x1;如何參與？ 用戶可通過完成活動頁面展示的當日任務列表來獲得字母卡，每完成一個任務即可隨機獲得一個字母，用戶集齊“TIGER”五個字母即可參與瓜分百萬股票代金券，每個用戶單日最多可獲得20張字母卡（不包括好友贈予和魔法卡）。 用戶在活動期間邀請累計7名好友完成註冊並開戶（註冊時間和開戶時間均在活動期間），即可獲得一張魔法卡（每人僅可獲得一張魔法卡）。魔法卡可用於兌換TIGER中的任意一個字母。&#x1;如果用戶的某一字母卡數量爲0，則字母卡爲灰色，用戶可通過點擊灰色的字母卡向好友索要卡片；如果用戶的字母卡數量大於0，則字母卡爲彩色，用戶可通過點擊彩色的字母卡向好友贈送卡片。當用戶集齊TIGER之後將無法再索要卡片或者贈送卡片。 &#x1; &#x1;如何獲得獎勵？ 用戶可在2021年7月1日至2021年7月2日期間進行開獎，所有集齊TIGER的客戶可點擊活動頁面的“開獎”按鈕，即可查看自己瓜分到的股票代金券獎勵。在開獎時間段內未點擊開獎的用戶將無法獲得獎勵。&#x1; 獎勵發放： 股票代金券將在開獎後的1個工作日內發放至用戶的獎勵中心，用戶需要在獎勵發放後的20天內前往【Tiger Trade APP &gt; 我的 &gt; 活動獎勵】領取，過期未領取的獎勵將自動失效。 重要提示： 本次7週年活動涉及不同國家和地區，由於各地區的監管要求不同，不同地區的活動獎勵會有所區別。欲知詳情，請點擊下方活動鏈接，登陸您的賬號，並點擊“活動規則“查看詳情。","listText":"老虎7週年給大家發福利了，集齊TIGER五個字母即有機會瓜分百萬獎金，你準備好了嗎？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可參與活動</a> &#x1;如何參與？ 用戶可通過完成活動頁面展示的當日任務列表來獲得字母卡，每完成一個任務即可隨機獲得一個字母，用戶集齊“TIGER”五個字母即可參與瓜分百萬股票代金券，每個用戶單日最多可獲得20張字母卡（不包括好友贈予和魔法卡）。 用戶在活動期間邀請累計7名好友完成註冊並開戶（註冊時間和開戶時間均在活動期間），即可獲得一張魔法卡（每人僅可獲得一張魔法卡）。魔法卡可用於兌換TIGER中的任意一個字母。&#x1;如果用戶的某一字母卡數量爲0，則字母卡爲灰色，用戶可通過點擊灰色的字母卡向好友索要卡片；如果用戶的字母卡數量大於0，則字母卡爲彩色，用戶可通過點擊彩色的字母卡向好友贈送卡片。當用戶集齊TIGER之後將無法再索要卡片或者贈送卡片。 &#x1; &#x1;如何獲得獎勵？ 用戶可在2021年7月1日至2021年7月2日期間進行開獎，所有集齊TIGER的客戶可點擊活動頁面的“開獎”按鈕，即可查看自己瓜分到的股票代金券獎勵。在開獎時間段內未點擊開獎的用戶將無法獲得獎勵。&#x1; 獎勵發放： 股票代金券將在開獎後的1個工作日內發放至用戶的獎勵中心，用戶需要在獎勵發放後的20天內前往【Tiger Trade APP &gt; 我的 &gt; 活動獎勵】領取，過期未領取的獎勵將自動失效。 重要提示： 本次7週年活動涉及不同國家和地區，由於各地區的監管要求不同，不同地區的活動獎勵會有所區別。欲知詳情，請點擊下方活動鏈接，登陸您的賬號，並點擊“活動規則“查看詳情。","text":"老虎7週年給大家發福利了，集齊TIGER五個字母即有機會瓜分百萬獎金，你準備好了嗎？ 戳我即可參與活動 \u0001如何參與？ 用戶可通過完成活動頁面展示的當日任務列表來獲得字母卡，每完成一個任務即可隨機獲得一個字母，用戶集齊“TIGER”五個字母即可參與瓜分百萬股票代金券，每個用戶單日最多可獲得20張字母卡（不包括好友贈予和魔法卡）。 用戶在活動期間邀請累計7名好友完成註冊並開戶（註冊時間和開戶時間均在活動期間），即可獲得一張魔法卡（每人僅可獲得一張魔法卡）。魔法卡可用於兌換TIGER中的任意一個字母。\u0001如果用戶的某一字母卡數量爲0，則字母卡爲灰色，用戶可通過點擊灰色的字母卡向好友索要卡片；如果用戶的字母卡數量大於0，則字母卡爲彩色，用戶可通過點擊彩色的字母卡向好友贈送卡片。當用戶集齊TIGER之後將無法再索要卡片或者贈送卡片。 \u0001 \u0001如何獲得獎勵？ 用戶可在2021年7月1日至2021年7月2日期間進行開獎，所有集齊TIGER的客戶可點擊活動頁面的“開獎”按鈕，即可查看自己瓜分到的股票代金券獎勵。在開獎時間段內未點擊開獎的用戶將無法獲得獎勵。\u0001 獎勵發放： 股票代金券將在開獎後的1個工作日內發放至用戶的獎勵中心，用戶需要在獎勵發放後的20天內前往【Tiger Trade APP > 我的 > 活動獎勵】領取，過期未領取的獎勵將自動失效。 重要提示： 本次7週年活動涉及不同國家和地區，由於各地區的監管要求不同，不同地區的活動獎勵會有所區別。欲知詳情，請點擊下方活動鏈接，登陸您的賬號，並點擊“活動規則“查看詳情。","images":[{"img":"https://static.tigerbbs.com/fd956a9c2fc9ee609753ae5f967072a7","width":"415","height":"616"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"},{"img":"https://static.tigerbbs.com/fe0400cc487fb56f85d401ab03df4d5e","width":"415","height":"356"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":830,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":181460810,"gmtCreate":1623407462830,"gmtModify":1704202756952,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Woooo hooo ??&nbsp;","listText":"Woooo hooo ??&nbsp;","text":"Woooo hooo ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/181460810","repostId":"1138970454","repostType":2,"repost":{"id":"1138970454","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623385949,"share":"https://ttm.financial/m/news/1138970454?lang=en_US&edition=fundamental","pubTime":"2021-06-11 12:32","market":"us","language":"en","title":"Tiger Broker has been honoured The Asset Triple A Sustainable Investing Awards 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1138970454","media":"Tiger Newspress","summary":"June 11/ Tiger Broker has been honoured with the following awared at The Asset Triple A Sustainable ","content":"<p>June&nbsp;11/&nbsp;Tiger Broker has been honoured with&nbsp;the&nbsp;following&nbsp;awared&nbsp;at&nbsp;The Asset Triple A Sustainable Investing Awards 2021&nbsp;for&nbsp;Institutional&nbsp;Investor,&nbsp;ETF&nbsp;and&nbsp;Asset&nbsp;Servicing&nbsp;Providers:</p><p><img src=\"https://static.tigerbbs.com/d2a1d625f288fc86245344e0a6275f6f\" tg-width=\"1096\" tg-height=\"354\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tiger Broker has been honoured The Asset Triple A Sustainable Investing Awards 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiger Broker has been honoured The Asset Triple A Sustainable Investing Awards 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-11 12:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June&nbsp;11/&nbsp;Tiger Broker has been honoured with&nbsp;the&nbsp;following&nbsp;awared&nbsp;at&nbsp;The Asset Triple A Sustainable Investing Awards 2021&nbsp;for&nbsp;Institutional&nbsp;Investor,&nbsp;ETF&nbsp;and&nbsp;Asset&nbsp;Servicing&nbsp;Providers:</p><p><img src=\"https://static.tigerbbs.com/d2a1d625f288fc86245344e0a6275f6f\" tg-width=\"1096\" tg-height=\"354\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TIGR":"老虎证券"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138970454","content_text":"June 11/ Tiger Broker has been honoured with the following awared at The Asset Triple A Sustainable Investing Awards 2021 for Institutional Investor, ETF and Asset Servicing Providers:","news_type":1,"symbols_score_info":{"TIGR":0.9}},"isVote":1,"tweetType":1,"viewCount":1005,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":183610076,"gmtCreate":1623327680095,"gmtModify":1704200950980,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Buy buy buy!! Fly fly fly!!!","listText":"Buy buy buy!! Fly fly fly!!!","text":"Buy buy buy!! Fly fly fly!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/183610076","repostId":"1111571294","repostType":2,"isVote":1,"tweetType":1,"viewCount":843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114418584,"gmtCreate":1623086809648,"gmtModify":1704195848023,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"That’s the way uh huh uh huh~","listText":"That’s the way uh huh uh huh~","text":"That’s the way uh huh uh huh~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/114418584","repostId":"2141239873","repostType":2,"repost":{"id":"2141239873","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623062347,"share":"https://ttm.financial/m/news/2141239873?lang=en_US&edition=fundamental","pubTime":"2021-06-07 18:39","market":"us","language":"en","title":"BRIEF-Ocugen Says Co And Bharat Entered Into That Certain First Amendment To Co-Development, Supply And Commercialization Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2141239873","media":"Reuters","summary":"June 7 (Reuters) - Ocugen Inc   :   * OCUGEN INC - ON JUNE 1, 2021, CO AND BHARAT ENTERED INTO THAT ","content":"<html><body><p>June 7 (Reuters) - Ocugen Inc   :</p><p>   * OCUGEN INC - ON JUNE 1, 2021, CO AND BHARAT ENTERED INTO THAT CERTAIN FIRST AMENDMENT TO CO-DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENT</p><p>   * OCUGEN INC - PARTIES AGREED TO EXPAND THE ORIGINAL OCUGEN TERRITORY TO INCLUDE THE UNITED STATES AND CANADA</p><p>   * OCUGEN INC -  PAID TO BHARAT $15 MILLION IMMEDIATELY UPON EXECUTION OF THE AMENDMENT</p><p>   * OCUGEN INC - FURTHER AGREED TO PAY TO BHARAT A MILESTONE PAYMENT OF $10 MILLION WITHIN 30 DAYS OF THE FIRST COMMERCIAL SALE OF COVAXIN IN CANADA.</p><p>   * OCUGEN INC -  PARTIES WILL SHARE ANY PROFITS GENERATED FROM THE COMMERCIALIZATION OF COVAXIN IN THE AMENDED OCUGEN TERRITORY</p><p>Source text () Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen Says Co And Bharat Entered Into That Certain First Amendment To Co-Development, Supply And Commercialization Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen Says Co And Bharat Entered Into That Certain First Amendment To Co-Development, Supply And Commercialization Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-07 18:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 7 (Reuters) - Ocugen Inc   :</p><p>   * OCUGEN INC - ON JUNE 1, 2021, CO AND BHARAT ENTERED INTO THAT CERTAIN FIRST AMENDMENT TO CO-DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENT</p><p>   * OCUGEN INC - PARTIES AGREED TO EXPAND THE ORIGINAL OCUGEN TERRITORY TO INCLUDE THE UNITED STATES AND CANADA</p><p>   * OCUGEN INC -  PAID TO BHARAT $15 MILLION IMMEDIATELY UPON EXECUTION OF THE AMENDMENT</p><p>   * OCUGEN INC - FURTHER AGREED TO PAY TO BHARAT A MILESTONE PAYMENT OF $10 MILLION WITHIN 30 DAYS OF THE FIRST COMMERCIAL SALE OF COVAXIN IN CANADA.</p><p>   * OCUGEN INC -  PARTIES WILL SHARE ANY PROFITS GENERATED FROM THE COMMERCIALIZATION OF COVAXIN IN THE AMENDED OCUGEN TERRITORY</p><p>Source text () Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FFBC":"第一金融银行股份","FBNC":"第一万能金控","OCGN":"Ocugen","FNLC":"第一万通金控","THFF":"First Financial Corporation Indi"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2141239873","content_text":"June 7 (Reuters) - Ocugen Inc   :   * OCUGEN INC - ON JUNE 1, 2021, CO AND BHARAT ENTERED INTO THAT CERTAIN FIRST AMENDMENT TO CO-DEVELOPMENT, SUPPLY AND COMMERCIALIZATION AGREEMENT   * OCUGEN INC - PARTIES AGREED TO EXPAND THE ORIGINAL OCUGEN TERRITORY TO INCLUDE THE UNITED STATES AND CANADA   * OCUGEN INC -  PAID TO BHARAT $15 MILLION IMMEDIATELY UPON EXECUTION OF THE AMENDMENT   * OCUGEN INC - FURTHER AGREED TO PAY TO BHARAT A MILESTONE PAYMENT OF $10 MILLION WITHIN 30 DAYS OF THE FIRST COMMERCIAL SALE OF COVAXIN IN CANADA.   * OCUGEN INC -  PARTIES WILL SHARE ANY PROFITS GENERATED FROM THE COMMERCIALIZATION OF COVAXIN IN THE AMENDED OCUGEN TERRITORYSource text () Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"FFBC":1,"OCGN":0.9,"FBNC":1,"FNLC":1,"THFF":1}},"isVote":1,"tweetType":1,"viewCount":806,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132114117,"gmtCreate":1622075651639,"gmtModify":1704178897919,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite","listText":"May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite","text":"May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132114117","repostId":"2138144615","repostType":2,"repost":{"id":"2138144615","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622075143,"share":"https://ttm.financial/m/news/2138144615?lang=en_US&edition=fundamental","pubTime":"2021-05-27 08:25","market":"us","language":"en","title":"BRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin","url":"https://stock-news.laohu8.com/highlight/detail?id=2138144615","media":"Reuters","summary":"May 26 (Reuters) - Ocugen Inc   :   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICAT","content":"<html><body><p>May 26 (Reuters) - Ocugen Inc   :</p><p>   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN</p><p>   * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR</p><p>   * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM FDA</p><p>   * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD &amp; DRUG ADMINISTRATION (FDA) IN JUNE</p><p>   * BELIEVE THAT FDA'S NEW GUIDANCE CONFIRMS THAT OCUGEN CONTINUES TO MEET ALL CRITERIA FOR SUBMISSION OF AN EUA</p><p>   * ONCE EUA APPLICATION HAS BEEN SUBMITTED, OCUGEN INTENDS TO COMMENCE PRE-BIOLOGICS LICENSE APPLICATION DISCUSSIONS WITH FDA</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-27 08:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>May 26 (Reuters) - Ocugen Inc   :</p><p>   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN</p><p>   * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR</p><p>   * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM FDA</p><p>   * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD &amp; DRUG ADMINISTRATION (FDA) IN JUNE</p><p>   * BELIEVE THAT FDA'S NEW GUIDANCE CONFIRMS THAT OCUGEN CONTINUES TO MEET ALL CRITERIA FOR SUBMISSION OF AN EUA</p><p>   * ONCE EUA APPLICATION HAS BEEN SUBMITTED, OCUGEN INTENDS TO COMMENCE PRE-BIOLOGICS LICENSE APPLICATION DISCUSSIONS WITH FDA</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138144615","content_text":"May 26 (Reuters) - Ocugen Inc   :   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN   * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR   * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING FEEDBACK FROM FDA   * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD & DRUG ADMINISTRATION (FDA) IN JUNE   * BELIEVE THAT FDA'S NEW GUIDANCE CONFIRMS THAT OCUGEN CONTINUES TO MEET ALL CRITERIA FOR SUBMISSION OF AN EUA   * ONCE EUA APPLICATION HAS BEEN SUBMITTED, OCUGEN INTENDS TO COMMENCE PRE-BIOLOGICS LICENSE APPLICATION DISCUSSIONS WITH FDASource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":100432838,"gmtCreate":1619627690324,"gmtModify":1704727100914,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>FDA kindly approve histo for emergency use ?????","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>FDA kindly approve histo for emergency use ?????","text":"$Histogenics(OCGN)$FDA kindly approve histo for emergency use ?????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/100432838","isVote":1,"tweetType":1,"viewCount":1416,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"content":"Yes! Finally its coming. stock pipling fOr more Guys!","text":"Yes! Finally its coming. stock pipling fOr more Guys!","html":"Yes! Finally its coming. stock pipling fOr more Guys!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106431901,"gmtCreate":1620138145403,"gmtModify":1704339194483,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>FDA &amp; EUA soon ???????","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>FDA &amp; EUA soon ???????","text":"$Histogenics(OCGN)$FDA & EUA soon ???????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/106431901","isVote":1,"tweetType":1,"viewCount":1064,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":108770729,"gmtCreate":1620058417161,"gmtModify":1704338075101,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Phase 3 trail gotta succeed soon! Comeon! ???????","listText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Phase 3 trail gotta succeed soon! Comeon! ???????","text":"$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Phase 3 trail gotta succeed soon! Comeon! ???????","images":[{"img":"https://static.tigerbbs.com/c65f9d0a9f97db6e86abf4e90d81ce1c","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/108770729","isVote":1,"tweetType":1,"viewCount":655,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":106432481,"gmtCreate":1620138340243,"gmtModify":1704339198599,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MVIS\">$Microvision(MVIS)$</a>Where’s the Reddit push to $100? Hahahah","listText":"<a href=\"https://laohu8.com/S/MVIS\">$Microvision(MVIS)$</a>Where’s the Reddit push to $100? Hahahah","text":"$Microvision(MVIS)$Where’s the Reddit push to $100? Hahahah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/106432481","isVote":1,"tweetType":1,"viewCount":1142,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3499670714821455","authorId":"3499670714821455","name":"Pherson","avatar":"https://static.tigerbbs.com/ac65897b5fc1c9a26e94c39d30108b35","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3499670714821455","idStr":"3499670714821455"},"content":"I said 10000 letter or not","text":"I said 10000 letter or not","html":"I said 10000 letter or not"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":106430920,"gmtCreate":1620137959860,"gmtModify":1704339191183,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Silent for way too long~ something should be cooking soon!!","listText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Silent for way too long~ something should be cooking soon!!","text":"$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Silent for way too long~ something should be cooking soon!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/106430920","isVote":1,"tweetType":1,"viewCount":1062,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3578811676095048","idStr":"3578811676095048"},"content":"Yea, i am sensing that too. Buying More to leverage!","text":"Yea, i am sensing that too. Buying More to leverage!","html":"Yea, i am sensing that too. Buying More to leverage!"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164587366,"gmtCreate":1624230013555,"gmtModify":1703830813306,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Note to self~","listText":"Note to self~","text":"Note to self~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/164587366","repostId":"1126454279","repostType":2,"isVote":1,"tweetType":1,"viewCount":1919,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":185502638,"gmtCreate":1623658135724,"gmtModify":1704207966754,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Naked gogogo","listText":"Naked gogogo","text":"Naked gogogo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/185502638","repostId":"1149061517","repostType":2,"isVote":1,"tweetType":1,"viewCount":773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":109704551,"gmtCreate":1619717396173,"gmtModify":1704271330197,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Time to fly high, soar away!! ??","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Time to fly high, soar away!! ??","text":"$Histogenics(OCGN)$Time to fly high, soar away!! ??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/109704551","isVote":1,"tweetType":1,"viewCount":816,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374554146,"gmtCreate":1619466288385,"gmtModify":1704724291910,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Awaiting the FDA approval~","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Awaiting the FDA approval~","text":"$Histogenics(OCGN)$Awaiting the FDA approval~","images":[{"img":"https://static.tigerbbs.com/366c085435b4a741f4b4bc05bab87afb","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374554146","isVote":1,"tweetType":1,"viewCount":821,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":191974032,"gmtCreate":1620839039326,"gmtModify":1704349217893,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IPW\">$iPower Inc.(IPW)$</a>??????","listText":"<a href=\"https://laohu8.com/S/IPW\">$iPower Inc.(IPW)$</a>??????","text":"$iPower Inc.(IPW)$??????","images":[{"img":"https://static.tigerbbs.com/082d817e92da6e685928e11314c2e7cf","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/191974032","isVote":1,"tweetType":1,"viewCount":458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":104441415,"gmtCreate":1620408256537,"gmtModify":1704343357559,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MVIS\">$Microvision(MVIS)$</a>Hodl only, only next week can see abit more of greens~","listText":"<a href=\"https://laohu8.com/S/MVIS\">$Microvision(MVIS)$</a>Hodl only, only next week can see abit more of greens~","text":"$Microvision(MVIS)$Hodl only, only next week can see abit more of greens~","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/104441415","isVote":1,"tweetType":1,"viewCount":1029,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154946922,"gmtCreate":1625473168066,"gmtModify":1703742360407,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Time to soar!","listText":"Time to soar!","text":"Time to soar!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154946922","repostId":"2148801599","repostType":2,"repost":{"id":"2148801599","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625576711,"share":"https://ttm.financial/m/news/2148801599?lang=en_US&edition=fundamental","pubTime":"2021-07-06 21:05","market":"us","language":"en","title":"Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2148801599","media":"Reuters","summary":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, ha","content":"<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen says Indian partner's vaccine 93.4% effective against severe COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-06 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148801599","content_text":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":132114117,"gmtCreate":1622075651639,"gmtModify":1704178897919,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite","listText":"May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite","text":"May it be approved soon then~ the discussion has been way too long.. already no joy upon the news, only the actual graph can excite","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/132114117","repostId":"2138144615","repostType":2,"repost":{"id":"2138144615","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1622075143,"share":"https://ttm.financial/m/news/2138144615?lang=en_US&edition=fundamental","pubTime":"2021-05-27 08:25","market":"us","language":"en","title":"BRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin","url":"https://stock-news.laohu8.com/highlight/detail?id=2138144615","media":"Reuters","summary":"May 26 (Reuters) - Ocugen Inc   :   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICAT","content":"<html><body><p>May 26 (Reuters) - Ocugen Inc   :</p><p>   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN</p><p>   * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR</p><p>   * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM FDA</p><p>   * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD &amp; DRUG ADMINISTRATION (FDA) IN JUNE</p><p>   * BELIEVE THAT FDA'S NEW GUIDANCE CONFIRMS THAT OCUGEN CONTINUES TO MEET ALL CRITERIA FOR SUBMISSION OF AN EUA</p><p>   * ONCE EUA APPLICATION HAS BEEN SUBMITTED, OCUGEN INTENDS TO COMMENCE PRE-BIOLOGICS LICENSE APPLICATION DISCUSSIONS WITH FDA</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ocugen Says On Track To Submit EUA Application To U.S. FDA For Its COVID-19 Vaccine Candidate, Covaxin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-27 08:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>May 26 (Reuters) - Ocugen Inc   :</p><p>   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN</p><p>   * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR</p><p>   * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING <a href=\"https://laohu8.com/S/FDBK.UK\">FEEDBACK</a> FROM FDA</p><p>   * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD &amp; DRUG ADMINISTRATION (FDA) IN JUNE</p><p>   * BELIEVE THAT FDA'S NEW GUIDANCE CONFIRMS THAT OCUGEN CONTINUES TO MEET ALL CRITERIA FOR SUBMISSION OF AN EUA</p><p>   * ONCE EUA APPLICATION HAS BEEN SUBMITTED, OCUGEN INTENDS TO COMMENCE PRE-BIOLOGICS LICENSE APPLICATION DISCUSSIONS WITH FDA</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2138144615","content_text":"May 26 (Reuters) - Ocugen Inc   :   * OCUGEN ON TRACK TO SUBMIT EMERGENCY USE AUTHORIZATION APPLICATION TO U.S. FDA FOR ITS COVID-19 VACCINE CANDIDATE, COVAXIN   * ACTIVE DISCUSSIONS WITH FDA RELATED TO COVAXIN INITIATED LATE LAST YEAR   * MASTER FILE SUBMITTED TO FDA ON MARCH 26, 2021; AWAITING FEEDBACK FROM FDA   * CONFIRMED ITS PLAN TO SUBMIT ITS EUA APPLICATION FOR COVAXIN TO U.S. FOOD & DRUG ADMINISTRATION (FDA) IN JUNE   * BELIEVE THAT FDA'S NEW GUIDANCE CONFIRMS THAT OCUGEN CONTINUES TO MEET ALL CRITERIA FOR SUBMISSION OF AN EUA   * ONCE EUA APPLICATION HAS BEEN SUBMITTED, OCUGEN INTENDS TO COMMENCE PRE-BIOLOGICS LICENSE APPLICATION DISCUSSIONS WITH FDASource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198352703,"gmtCreate":1620934658202,"gmtModify":1704350693558,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>18-20% surge can’t be all we got right…. ☝?☝?","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>18-20% surge can’t be all we got right…. ☝?☝?","text":"$Naked Brand(NAKD)$18-20% surge can’t be all we got right…. ☝?☝?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/198352703","isVote":1,"tweetType":1,"viewCount":676,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198353863,"gmtCreate":1620932289152,"gmtModify":1704350687575,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>+8% to +10% now, what are the chances post market +50%? Hmm ?&nbsp;","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>+8% to +10% now, what are the chances post market +50%? Hmm ?&nbsp;","text":"$Naked Brand(NAKD)$+8% to +10% now, what are the chances post market +50%? Hmm ?","images":[{"img":"https://static.tigerbbs.com/232e738544f046976097799c1859a843","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/198353863","isVote":1,"tweetType":1,"viewCount":647,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":199937181,"gmtCreate":1620661395243,"gmtModify":1704346400639,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Today financial report, hope all is good ?? it has been WAYYYYY too long since there is any much movement from this!","listText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Today financial report, hope all is good ?? it has been WAYYYYY too long since there is any much movement from this!","text":"$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Today financial report, hope all is good ?? it has been WAYYYYY too long since there is any much movement from this!","images":[{"img":"https://static.tigerbbs.com/9dd3683913de87a812e74b9342ebec2b","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/199937181","isVote":1,"tweetType":1,"viewCount":464,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":100437798,"gmtCreate":1619627994214,"gmtModify":1704727105116,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>It’s about time right?","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>It’s about time right?","text":"$Histogenics(OCGN)$It’s about time right?","images":[{"img":"https://static.tigerbbs.com/ce069da250fec60bf526a73af59f6c4e","width":"750","height":"1224"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/100437798","isVote":1,"tweetType":1,"viewCount":906,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":100434843,"gmtCreate":1619627884282,"gmtModify":1704727103340,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Really need to hold till clinical trial phase 3 to see it ? again","listText":"<a href=\"https://laohu8.com/S/RVPH\">$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$</a>Really need to hold till clinical trial phase 3 to see it ? again","text":"$Reviva Pharmaceuticals Holdings, Inc.(RVPH)$Really need to hold till clinical trial phase 3 to see it ? again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/100434843","isVote":1,"tweetType":1,"viewCount":737,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374554942,"gmtCreate":1619466169086,"gmtModify":1704724291583,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Time to soar ?? 14-15 tomorrow will be good ????","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCGN)$</a>Time to soar ?? 14-15 tomorrow will be good ????","text":"$Histogenics(OCGN)$Time to soar ?? 14-15 tomorrow will be good ????","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/374554942","isVote":1,"tweetType":1,"viewCount":446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154941707,"gmtCreate":1625473069409,"gmtModify":1703742357615,"author":{"id":"3582000739695630","authorId":"3582000739695630","name":"Raymond1109","avatar":"https://static.tigerbbs.com/6bcd5134cf658a22c90379139fc8ea6f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582000739695630","idStr":"3582000739695630"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154941707","repostId":"155231719","repostType":1,"repost":{"id":155231719,"gmtCreate":1625438214331,"gmtModify":1703741555205,"author":{"id":"3564546889826365","authorId":"3564546889826365","name":"koonkoon","avatar":"https://static.tigerbbs.com/5dcc75085d1205dc8567a05395bac661","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3564546889826365","idStr":"3564546889826365"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCG</a>n)good news","listText":"<a href=\"https://laohu8.com/S/OCGN\">$Histogenics(OCG</a>n)good news","text":"$Histogenics(OCGn)good news","images":[{"img":"https://static.tigerbbs.com/289870db1bfd26ce1e7e3a3fe788f25c","width":"1080","height":"975"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/155231719","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}